Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monosialoganglioside in Acute Ischemic Stroke
NCT06742216Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Monosialoganglioside with Placebo (2 arms). Primary endpoint: Proportion of modified Rankin Scale (mRS) 0-2 at 90 days. Started Nov 2020; status: completed.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06742216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742216.